China's drug regulator is set to give the green light for the first foreign-made mRNA vaccine.
Shanghai-based Fosun Pharma said the National Medical Products Administration (NMPA) recently completed an expert panel review of an mRNA Covid-19 vaccine co-developed by the company and German firm BioNTech.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
